denosumab

The FDA has approved Amgen's osteoporosis drug denosumab for use by cancer patients with solid tumors whose disease has metastasized to their bones. The indication to prevent complications such as fractures and bone pain among those patients could boost the drug's sales by billions.

Several biotech stocks were on the move Monday after Deutsche Bank started rating them. The bank's analyst, Robyn Karnauskas, took a generally wary view on the biotech sector, putting buy ratings only on Gilead and Dendreon.

Amgen, the world's largest biotechnology company, reported fourth-quarter results that missed Wall Street's expectations, as a 2% increase in sales failed to translate into a stronger bottom line.

It seems that when it comes to Aranesp, its blockbuster anemia drug, Amgen (AMGN) just can't catch a break, nor for that matter, create one. Recently, Amgen was hit with a double whammy -- a lawsuit and an unfavorable study of the drug. On Tuesday, yet another study confirmed that cancer patients...

Drugmaker Amgen (AMGN) did not win the Food & Drug Administration's approval on Monday for its experimental osteoporosis treatment denosumab. Amgen, based in Thousand Oaks, Calif., had been banking on the drug's approval for company growth, but the FDA asked for more information before making a...

No doubt, Amgen (AMGN) and its investors would have liked the U.S. Food and Drug Administration's health panel proceedings to have gone differently. The good news coming out of the panel, held on Thursday, was that Amgen's highly anticipated bone drug, denosumab, benefits patients with...

It's great when a biotech company can deliver on a promising drug. Although Amgen Inc. (AMGN) reported disappointing earnings in the first quarter, many investors put their hopes up on its experimental denosumab bone drug for treating post-menopausal osteoporosis. This drug, which was filed for...

Amgen Inc. (AMGN) reported first-quarter results after the closing bell yesterday. The world's biggest biotechnology company said its net income, on an adjusted basis, fell 8 percent to $1.12 billion, or $1.08 per share as sales slumped. Revenue decreased 8 percent to $3.3 billion. The results were...